Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.

@article{Nakano2012FeasibilityAE,
  title={Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.},
  author={Kenji Nakano and Shunji Takahashi and Takeshi Yuasa and Noriko Nishimura and Yuko Mishima and Sakura Sakajiri and M. Yokoyama and Naoko Tsuyama and Yuichi Ishikawa and Kiyohiko Hatake},
  journal={Japanese journal of clinical oncology},
  year={2012},
  volume={42 8},
  pages={697-703}
}
OBJECTIVE No standard treatment has been established for poorly differentiated neuroendocrine carcinoma; the usual recommended treatment is based on the strategy for small cell lung carcinoma. The aim of this study was to evaluate the response of poorly differentiated neuroendocrine carcinoma to the combination of irinotecan and cisplatin in one institution… CONTINUE READING